NMR vs UBS

For growth investors, Nomura Holdings, Inc.

(NMR) is the stronger pick with 5. 6% revenue growth year-over-year, versus -20. 4% for UBS Group AG (UBS). Nomura Holdings, Inc. (NMR) offers the better valuation at 10. 4x trailing P/E (9. 7x forward), making it the more compelling value choice. Analysts rate UBS Group AG (UBS) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Nomura Holdings, Inc.

(NMR) is the cheapest at 10. 4x versus UBS Group AG at 23. 7x. On forward P/E, Nomura Holdings, Inc. is actually cheaper at 9. 7x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Nomura Holdings, Inc. wins at 0. 49x versus UBS Group AG's 12. 29x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, UBS Group AG (UBS) delivered a total return of +204.

7%, compared to +68. 5% for Nomura Holdings, Inc. (NMR). Over 10 years, the gap is even starker: UBS returned +232. 0% versus NMR's +141. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), UBS Group AG (UBS) is the lower-risk stock at 1.

17β versus Nomura Holdings, Inc. 's 1. 32β — meaning NMR is approximately 13% more volatile than UBS relative to the S&P 500. On balance sheet safety, UBS Group AG (UBS) carries a lower debt/equity ratio of 4% versus 4% for Nomura Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nomura Holdings, Inc.

(NMR) is pulling ahead at 5. 6% versus -20. 4% for UBS Group AG (UBS). On earnings-per-share growth, the picture is similar: UBS Group AG grew EPS 23. 0% year-over-year, compared to 7. 2% for Nomura Holdings, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

UBS Group AG (UBS) is the more profitable company, earning 10.

4% net margin versus 7. 6% for Nomura Holdings, Inc. — meaning it keeps 10. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UBS leads at 11. 9% versus 11. 3% for NMR. At the gross margin level — before operating expenses — UBS leads at 63. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Nomura Holdings, Inc. (NMR) is the more undervalued stock at a PEG of 0. 49x versus UBS Group AG's 12. 29x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Nomura Holdings, Inc. (NMR) trades at 9. 7x forward P/E versus 13. 6x for UBS Group AG — 3. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NMR: -26. 8% to $5. 79.

All stocks in this comparison pay dividends.

Nomura Holdings, Inc. (NMR) offers the highest yield at 4. 8%, versus 1. 6% for UBS Group AG (UBS).

For long-horizon retirement investors, UBS Group AG (UBS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

17), 1. 6% yield, +232. 0% 10Y return). Both have compounded well over 10 years (UBS: +232. 0%, NMR: +141. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Financial Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NMR is a mid-cap deep-value stock; UBS is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.